上海凯宝(300039) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 reached ¥256,909,136.47, an increase of 49.19% compared to the same period last year[3] - Net profit attributable to shareholders was ¥33,707,925.29, reflecting a growth of 17.06% year-on-year[3] - The net profit excluding non-recurring gains and losses was ¥28,228,859.31, up by 8.59% from the previous year[3] - Total operating revenue for the period reached ¥794,949,444.36, an increase from ¥647,783,882.97 in the previous period, representing a growth of approximately 22.7%[31] - The net profit for the current period is 115,498,710.67, an increase from 105,737,382.21 in the previous period, representing a growth of approximately 7.4%[34] - The total profit for the current period is 142,151,129.24, compared to 126,614,022.41 in the previous period, reflecting an increase of approximately 12.5%[34] - The company reported a total operating profit of 143,456,457.81, an increase from 129,613,820.45 in the previous period[34] - The company reported a net profit margin improvement, with net profit increasing due to higher revenue and controlled costs[31] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥3,285,094,604.80, representing a 14.17% increase from the end of the previous year[3] - The total assets increased to ¥3,285,094,604.80 from ¥2,877,284,200.91, marking a growth of around 14.1%[31] - Total liabilities decreased to ¥249,514,010.00 from ¥298,959,816.78, a reduction of approximately 16.6%[31] - The equity attributable to shareholders of the parent company rose to ¥3,035,580,594.80 from ¥2,578,324,384.13, an increase of about 17.7%[31] Cash Flow - The company's cash flow from operating activities showed a net decrease of 52.42%, totaling ¥102,751,921.59 year-to-date[11] - The net cash flow from operating activities is 102,751,921.59, down from 215,975,326.69 in the previous period, indicating a decrease of approximately 52.5%[41] - Cash inflow from investment activities totals 1,462,513,124.76, compared to 2,414,944,920.27 in the previous period, a decrease of about 39.4%[41] - The net cash flow from investment activities is 3,719,861.29, a significant improvement from -104,118,463.44 in the previous period[41] - The cash and cash equivalents at the end of the period amount to 341,816,258.94, up from 98,650,340.02 in the previous period[41] Investments and Acquisitions - The company plans to acquire over 51% of Shanghai Gebaide Biotechnology Co., Ltd. after the completion of Phase III clinical trials for a new drug, with an estimated valuation of RMB 480 million[17] - The company invested RMB 10 million to establish Shanghai Kaihe Jiao Medical Technology Co., Ltd., holding a 75% stake, focusing on chiral materials for medical applications[21] - The company has identified potential risks in a private equity fund investment, estimating a recoverable amount of RMB 15,887,200 based on various scenarios[21] - The company’s investment in the private equity fund totaled RMB 100 million, with RMB 864,000 returned by the end of the third quarter of 2021[21] - The company is in the process of acquiring land use rights, with updates to be disclosed as per regulations[21] Shareholder Information - The company’s major shareholders include Mu Jingwei with 125,873,527 shares and Zhang Yanqi with 160,790,370 shares[15] - The company’s total restricted shares at the end of the period were 129,433,306, with 148,425 shares released during the period[16] Operating Costs and Expenses - The company experienced a 33.31% increase in operating costs year-to-date, attributed to higher sales revenue[10] - Total operating costs amounted to ¥663,967,428.89, up from ¥544,345,297.28, indicating an increase of about 22%[31] - Research and development expenses were ¥31,986,225.60, a decrease from ¥41,170,561.35, reflecting a reduction of approximately 22.2%[31] Other Financial Metrics - The weighted average return on equity for the year-to-date was 4.39%, an increase of 0.30% compared to the previous year[3] - The total comprehensive income for the first nine months of 2021 increased by 362.12%, mainly due to the fair value changes of investments[10] - The company has made strategic investments in long-term equity investments, increasing from ¥248,190,000.00 to ¥621,327,500.00, reflecting a growth of approximately 150%[28] - The cash and cash equivalents amounted to RMB 1,332,194,593.06, while trading financial assets decreased to RMB 68,907,408.67 from RMB 114,647,286.37[22] - Accounts receivable stood at RMB 321,481,008.66, slightly up from RMB 319,556,080.91 in the previous period[22] - Cash and cash equivalents increased significantly, with other current assets rising to ¥10,752,772.18 from ¥1,887,773.21, a growth of approximately 469%[28] - The total comprehensive income attributable to the parent company is 105,737,382.21 for the current period[37] - The basic and diluted earnings per share are both 0.1011[37]